A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?

Drug and Alcohol Dependence

Volumn 142, Issue , 2014, Pages 46-55

  Larance, Briony ^a   Carragher, Natacha ^a   Mattick, Richard P ^a   Lintzeris, Nicholas ^b,c   Ali, Robert ^d,e   Degenhardt, Louisa ^a,f,g,h  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b South East Sydney and Illawarra Health Services   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e Drug & Alcohol Services South Australia   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Buprenorphine; Compliance; Diversion; Injection; Methadone; Supervised dosing

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; NARCOTIC ANTAGONIST;

ADULT; AGE; ANALYSIS; ARTICLE; CHILD WELFARE; CLINICAL INDICATOR; COMORBIDITY; CROSS-SECTIONAL STUDY; DRUG DOSE REGIMEN; DRUG USE; FEMALE; FOLLOW UP; HOSPITAL MANAGEMENT; HUMAN; LATENT CLASS ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SELF REPORT; SEX DIFFERENCE; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; STRUCTURED QUESTIONNAIRE; OPIOID-RELATED DISORDERS; PSYCHOLOGY; THEORETICAL MODEL;

AGE FACTORS; BUPRENORPHINE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; METHADONE; MODELS, THEORETICAL; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SELF REPORT;

EID: 84905561685     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.05.018     Document Type: Article

References (52)

1. Ahn J., McCoombs J.S., Jung C., Croudace T.J., McDonnell D., Ascher-Svanum H., Edgell E.T., Shi L. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) Program. Value Health 2008, 11:48-56.
2. Akaike H. A new look at the statistical model identification. IEEE T. Automat. Control 1974, 19:716-723.
3. Amato L., Davoli M., Perucci C.A., Ferri M., Faggiano F., Mattick R.P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J. Subst. Abuse Treat. 2005, 28:321-329.
4. Australasian Chapter of Addiction Medicine Clinical Guidelines: Assessing Suitability for Unsupervised Medication Doses in the Treatment of Opioid Dependency 2006, Adult Medicine Division, The Royal Australian College of Physicians, Sydney.
5. Australian Institute of Health Welfare National Opioid Pharmacotherapy Statistics Annual Data collection: 2007 Report 2008, AIHW, Canberra.
6. Bell J., Ryan A., Mutch C., Batey R., Rea F. Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: follow-up of a randomised trial. Drug Alcohol Depend. 2008, 96:183-186.
7. Bell J., Shanahan M., Mutch C., Rea F., Ryan A., Batey R., Dunlop A., Winstock A. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007, 102:1899-1907.
8. Carragher N., Adamson G., Bunting B., McCann S. Subtypes of depression in a nationally representative sample. J. Affect. Disord. 2009, 113:88-99.
9. Carragher N., McWilliams L.A. A latent class analysis of DSM-IV criteria for pathological gambling: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychiatry Res. 2011, 187:185-192.
10. Croudace T.J., Jarvelin M.-R., Wadsworth M.E.J., Jones P.B. Developmental typology of trajectories to nighttime bladder control: epidemiologic application of longitudinal latent class analysis. Am. J. Epidemiol. 2003, 157:834-842.
11. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998, 51:253-263.
12. Deering D.E.A., Sheridan J., Sellman J.D., Adamson S.J., Pooley S., Robertson R., Henderson C. Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness. Addict. Behav. 2011, 36:636-642.
13. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M., McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011, 106:32-51.
14. Degenhardt L., Larance B., Mathers B., Azim T., Kamarulzaman A., Mattick R.P., Panda S., Toufik A., Tyndall M., Wiessing L., Wodak A. Benefits and Risks of Pharmaceutical Opioids: Essential Treatment and Diverted Medication. A Global Review of Availability, Extra-Medical Use, Injection and the Association With HIV. Thematic Paper Undertaken On Behalf of the Reference Group to the United Nations on HIV and Injecting Drug Use National Drug And Alcohol Research Centre 2008, University of New South Wales, Sydney.
15. Department of Health and Ageing National Pharmacotherapy Policy for People Dependent on Opioids 2007, Commonwealth of Australia, Canberra.
16. Drugs and Poisons Regulation Group Policy for Maintainance Pharmacotherapy for Opioid Dependence. Drugs Policy and Services Branch 2006, Department of Human Sciences, State of Victoria.
17. Drugs of Dependence Unit, 2006. Policy relating to the use of Suboxone (buprenorphine and naloxone) and Subutex (buprenorphine) in opioid dependence treatment programs. Drug and Alcohol Services South Australia, Government of South Australia.
18. Drugs of Dependence Unit Policy for Non-supervised Dosing of Methadone and Buprenorphine in Opioid Dependence Treatment Programs 2007, Drug and Alcohol Services South Australia, Government of South Australia.
19. Dunbar J. Adherence measures and their utility. Control Clin. Trials 1984, 5:515-521.
20. Gerra G., Saenz E., Busse A., Maremmani I., Ciccocioppo R., Zaimovic A., Gerra M.L., Amore M., Manfredini M., Donnini C., Somaini L. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:483-489.
21. Gowing L., Farrell M., Bornemann R., Sullivan L.E., Ali R. Oral substitution treatment of injecting drug users for prevention of HIV infection. Cochrane Database Syst. Rev. 2011, 10:CD004145. 10.1002/14651858.CD004145.pub4.
22. Gunderson E.W., Wang X.-Q., Fiellin D.A., Bryan B., Levin F.R. Unobserved versus office buprenorphine/naloxone induction: a pilot randomised clinical trial. Addict. Behav. 2010, 35:537-540.
23. Hall W. Methadone Maintenance Treatment as a Crime Control Measure, Crime and Justice Bulletin No. 29 1996, NSW Bureau of Crime Statistics and Research, Sydney.
24. Hansen R.A., Kim M.M., Song L., Tu W., Wu J., Murray M.D. Comparison of methods to assess medication adherence and classify nonadherence. Ann. Pharmacother. 2009, 43:413-422.
25. Haskew M., Wolff K., Dunn J., Bearn J. Patterns of adherence to oral methadone: implications for prescribers. J. Subst. Abuse Treat. 2008, 35:109-115.
26. Haynes R.B., Ackloo E., Sahota N., McDonald H.P., Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst. Rev. 2008, CD000011. 10.001002/14651858.CD14000011.pub14651853.
27. Henry-Edwards, S., Gowing, L., White, J., Ali, R., Bell, J., Brough, R., Lintzeris, N., Ritter, A., Quigley, A., 2003. Clinical guidelines and procedures for the use of methadone in the maintenance treatment of opioids dependence. Australian Government Department of Health and Ageing, Commonwealth of Australia.
28. Julius R.J., Novitsky M.A.J., Dubin W.R. Medication adherence: a review of the literature and implications for clinical practice. J. Psychiatr. Pract. 2009, 15:34-44.
29. Larance B., Degenhardt L., Lintzeris N., Bell J., Winstock A., Dietze P., Mattick R., Ali R., Horyniak D. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing. Drug Alcohol Depend. 2011, 118:265-273.
30. Larance B., Degenhardt L., Lintzeris N., Winstock A., Mattick R. Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug Alcohol Rev. 2011, 30:236-245.
31. Larance B., Degenhardt L., O'Brien S., Lintzeris N., Winstock A., Mattick R.P., Bell J., Ali R. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients. Drug Alcohol Rev. 2011, 30:613-620.
32. Lintzeris, N., Clark, N., Winstock, A., Dunlop, A., Gowing, L., Ritter, A., Bell, J., Quigley, A.J., Mattick, R.P., Monheit, B., White, J., 2006. National clinical guidelines and procedures for the use of buprenorphine in the maintenance treatment of opoid dependence. Australian Government National Drug Strategy, Commonwealth of Australia.
33. Lintzeris N., Pritchard E., Sciacchitano L. Investigation of Methadone Dosing in Victoria: Factors Influencing Dosing Levels 2007, Turning Point Alcohol and Drug Centre, Melbourne.
34. Lo Y., Mendell N., Rubin D. Testing the number of components in a normal mixture. Biometrika 2001, 88:767-778.
35. Madden A., Lea T., Bath N., Winstock A.R. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug Alcohol Rev. 2008, 27:671-678.
36. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009, 2:CD002209. 10.1002/14651858.CD002209.pub2.
37. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008, 2008:CD002207. 10.1002/14651858.CD002207.pub3.
38. McCutcheon A.L. Latent Class Analysis 1987, Cambridge University Press, Cambridge.
39. Mental Health and Drug and Alcohol Office New South Wales Opioid Treatment Program: Clinical Guidelines for Methadone and Buprenorphine Treatment of Opioid Dependence 2006, NSW Department of Health, Sydney.
40. Muthen L.K., Muthen B.O. Mplus User's Guide (1998-2007) 2007, Muthén & Muthén, Los Angeles, CA. fifth ed.
41. Nylund K.L., Asparouhov T., Muthén B.O. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct. Equ. Model. 2007, 14:535-569.
42. Padaiga Z., Subata E., Vanagas G. Outpatient methadone maintenance treatment program. Quality of life and health of opioid-dependent persons in Lithuania. Medicina (Kaunas) 2007, 43:235-241.
43. Ramaswamy V., DeSarbo W.S., Reibstein D.J., Robinson W.T. An empirical pooling approach for estimating marketing mix elasticities with PIMS data. Market. Sci. 1993, 12:103-124.
44. Ritter A., Di Natale R. The relationship between take-away methadone policies and methadone diversion. Drug Alcohol Rev. 2005, 24:347-352.
45. Schwartz G. Estimating the dimension of a model. Ann. Statist. 1978, 6:461-464.
46. Sclove L. Application of model-selection criteria to some problems in multivariate analysis. Psychometrika 1987, 52:333-343.
47. Strang J., Hall W., Hickman M., Bird S.M. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. BMJ 2010, 341:c4851.
48. Ward J., Mattick R.P., Hall W. Methadone Maintenance Treatment and Other Opioid Replacement Therapies 1998, Harwood Academic Publishers, Amsterdam.
49. Winstock A., Lea T. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia. Subst. Use Misuse 2010, 45:240-252.
50. Winstock A., Lea T., Madden A., Bath N. Knowledge about buprenorphine and methadone among those receiving treatment for opioid dependence. Drugs Educ. Prev. Pol. 2008, 15:395-409.
51. Winstock A., Lea T., Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Int. J. Drug Policy 2008, 19:450-458.
52. World Health Organization Guidelines For The Psychosocially Assisted Pharmacological Treatment Of Opioid Dependence 2009, WHO Press, Geneva.